Related Experiment Video
Updated: Aug 9, 2026
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
Published on: December 23, 2014
C1-esterase inhibitor transfusions in patients with hereditary angioedema
D E Visentin1, W H Yang, J Karsh
1Section of Allergy and Clinical Immunology, Ottawa Civic Hospital, University of Ottawa, Ontario, Canada.
Insights
C1-esterase inhibitor (C1-INH) transfusions effectively treated hereditary angioedema attacks in Canadian patients. This treatment provided rapid symptom relief with no adverse effects reported, though availability remains a concern.
Area of Science:
- Immunology
- Hematology
- Genetics
Background:
- Hereditary angioedema (HAE) is caused by C1-esterase inhibitor (C1-INH) deficiency.
- C1-INH replacement therapy is a potential definitive treatment for HAE attacks.
- Access to C1-INH in Canada is limited to compassionate use at specific centers.
Purpose of the Study:
- To evaluate the efficacy of C1-INH transfusions for HAE attacks.
- To assess patient satisfaction and safety of C1-INH transfusions.
- To understand the treatment's impact at a single Canadian institution.
Main Methods:
- Retrospective chart review of transfusion data (1995-1996).
- Patient interviews to gather treatment opinions.
- Collected data on attack frequency, duration, C1-INH dosage, and side effects.
Main Results:
- Seven of 13 HAE patients received C1-INH transfusions.
- 87 attacks were treated with over 100,000 units of C1-INH.
- Mean attack abatement time was 50 ± 8 minutes post-transfusion.
- No adverse effects were reported; patients expressed satisfaction but noted availability concerns.
Conclusions:
- C1-INH transfusion is an effective treatment for hereditary angioedema attacks.
- The therapy demonstrates rapid symptom resolution and a favorable safety profile.
- Patient satisfaction is high, underscoring the need for improved C1-INH accessibility.
Background:
Hereditary angioedema results from the deficiency of C1-esterase inhibitor (C1-INH), and C1-INH replacement would represent definitive treatment for angioedema attacks. In Canada, C1-INH is available only on a compassionate basis at select medical facilities. Our objective is to assess the efficacy of C1-INH transfusions during angioedema attacks at a single Canadian institution.
Methods:
A retrospective chart review of transfusion data between January 1, 1995 and June 30, 1996 was performed. Phone interviews with patients elicited their opinions of the treatment. Data collected included the number and duration of angioedema attacks, dose of transfused C1-INH, and side effects of treatment.
Results:
Of a cohort of 13 patients with hereditary angioedema, seven received transfusions with C1-INH. Attacks totaled 87, and more than 100,000 units of the product were transfused. The mean time for abatement of an attack after initiation of transfusion was 50 +/- 8 minutes (1 SD). There were no reports of adverse effects. Although patients were satisfied with the treatment, they raised concerns regarding long-term safety and availability.
Conclusions:
C1-INH transfusion is a satisfactory means of treating angioedema attacks.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:19Cerebral Edema l: Introduction
01:21Cytotoxic Edema: Pathophysiology